Lyell Immunopharma, Inc. (LYEL): who owns it and who trades it
As of Nov 16, 2026, LYEL insiders reported 29 open-market sales worth $613K and 2 purchases worth $37.5M in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Lynn Seely (CEO), with $355K. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Lyell Immunopharma
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns LYEL
87 funds and institutions reported LYEL shares worth $170M at the end of Q2 2026, about 52% of the company. The largest holder is ARCH Venture Management, LLC with 13.9%.
Funds and institutions (13F) 52%Everyone else 48%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| ARCH Venture Management, LLC | 3.25M | 13.93% | $45.5M | No change |
| GSK plc | 1.51M | 6.49% | $21.3M | No change |
| Vanguard Capital Management LLC | 786,774 | 3.38% | $11.1M | +10% |
| Orland Properties Ltd | 754,698 | 3.24% | $10.6M | No change |
| BlackRock, Inc. | 724,342 | 3.11% | $10.2M | +278% |
| Almitas Capital LLC | 581,407 | 2.49% | $8.2M | +1% |
| Foresite Capital Management V, LLC | 476,386 | 2.04% | $6.7M | -0% |
| Millennium Management LLC | 367,473 | 1.58% | $5.2M | -20% |
| Opaleye Management Inc. | 344,025 | 1.48% | $4.8M | +335% |
| VenBio Partners LLC | 337,697 | 1.45% | $4.7M | No change |
| Geode Capital Management, LLC | 310,636 | 1.33% | $4.4M | +86% |
| Alphabet Inc. | 293,256 | 1.26% | $4.1M | No change |
| State Street Corp | 185,322 | 0.80% | $2.6M | +156% |
| HSG Holding Ltd | 152,299 | 0.65% | $2.1M | New |
| Renaissance Technologies LLC | 130,190 | 0.56% | $1.8M | +12% |
| Northern Trust Corp | 118,500 | 0.51% | $1.7M | +291% |
| Qube Research & Technologies Ltd | 110,531 | 0.47% | $1.6M | +101% |
| Charles Schwab Investment Management Inc | 107,570 | 0.46% | $1.5M | +25% |
| Sixth Street Partners Management Company, L.P. | 107,570 | 0.46% | $1.5M | New |
| Marshall Wace, LLP | 106,300 | 0.46% | $1.5M | -28% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, LYEL insiders reported $37.5M of open-market purchases and $613K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 10, 2026 | Veronica Sanchez Bulis | Vice president | Sale | 416 | $15.93 | $6.6K | Form 4 |
| Nov 10, 2026 | Stephen J. Hill | Chief Operating Officer | Sale | 88 | $15.93 | $1.4K | Form 4 |
| Nov 10, 2026 | Gary K. Lee | Chief Scientific Officer | Sale | 129 | $15.93 | $2.1K | Form 4 |
| Nov 10, 2026 | Lynn Seely | CEO | Sale | 545 | $15.93 | $8.7K | Form 4 |
| Nov 4, 2026 | ARCH Venture Partners IX, LLC +4 | 10% owner | Purchase | 2.32M | $10.77 | $25M | Form 4 |
| Oct 12, 2026 | Jarrad Mattieu Aguirre | Chief Medical Officer | Sale | 422 | $8.63 | $3.6K | Form 4 |
| Sep 10, 2026 | David Shook | Chief Medical Officer | Sale | 500 | $12.70 | $6.3K | Form 4 |
| Aug 21, 2026 | Lynn Seely | CEO | Sale | 9,589 | $15.54 | $149K | Form 4 |
| Aug 21, 2026 | Stephen J. Hill | Chief Operating Officer | Sale | 989 | $15.54 | $15.4K | Form 4 |
| Aug 21, 2026 | Gary K. Lee | Chief Scientific Officer | Sale | 1,457 | $15.54 | $22.6K | Form 4 |
| Aug 10, 2026 | Veronica Sanchez Bulis | Vice president | Sale | 621 | $14.34 | $8.9K | Form 4 |
| Aug 10, 2026 | Gary K. Lee | Chief Scientific Officer | Sale | 131 | $14.34 | $1.9K | Form 4 |
| Aug 10, 2026 | Stephen J. Hill | Chief Operating Officer | Sale | 89 | $14.34 | $1.3K | Form 4 |
| Aug 10, 2026 | Lynn Seely | CEO | Sale | 390 | $14.34 | $5.6K | Form 4 |
| Jul 17, 2026 | Innovative Cellular Therapeutics Holdings Ltd | 10% owner | Sale | 10 | $13.70 | $137 | Form 4 |
| Jul 16, 2026 | Innovative Cellular Therapeutics Holdings Ltd | 10% owner | Sale | 10 | $13.73 | $137 | Form 4 |
| Jun 10, 2026 | David Shook | Chief Medical Officer | Sale | 1,977 | $12.64 | $25K | Form 4 |
| May 11, 2026 | Lynn Seely | CEO | Sale | 388 | $18.91 | $7.3K | Form 4 |
| May 11, 2026 | Gary K. Lee | Chief Scientific Officer | Sale | 130 | $18.92 | $2.5K | Form 4 |
| May 11, 2026 | Stephen J. Hill | Chief Operating Officer | Sale | 89 | $18.92 | $1.7K | Form 4 |
| May 11, 2026 | Veronica Sanchez Bulis | Vice president | Sale | 217 | $18.91 | $4.1K | Form 4 |
| Mar 6, 2026 | ARCH Venture Partners IX Overage, L.P. +4 | 10% owner | Purchase | 488,090 | $25.61 | $12.5M | Form 4 |
| Feb 11, 2026 | Lynn Seely | CEO | Sale | 7,455 | $23.39 | $174K | Form 4 |
| Feb 11, 2026 | Stephen J. Hill | Chief Operating Officer | Sale | 1,236 | $23.39 | $28.9K | Form 4 |
| Feb 11, 2026 | Gary K. Lee | Chief Scientific Officer | Sale | 1,671 | $23.39 | $39.1K | Form 4 |
| Feb 10, 2026 | Stephen J. Hill | Chief Operating Officer | Sale | 109 | $23.12 | $2.5K | Form 4 |
| Feb 10, 2026 | Gary K. Lee | Chief Scientific Officer | Sale | 147 | $23.12 | $3.4K | Form 4 |
| Feb 10, 2026 | Lynn Seely | CEO | Sale | 438 | $23.12 | $10.1K | Form 4 |
| Feb 10, 2026 | Veronica Sanchez Bulis | Vice president | Sale | 254 | $23.12 | $5.9K | Form 4 |
| Dec 30, 2025 | Veronica Sanchez Bulis | Vice president | Sale | 936 | $32.32 | $30.3K | Form 4 |
| Dec 24, 2025 | Veronica Sanchez Bulis | Vice president | Sale | 1,136 | $38.67 | $43.9K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| ARCH Venture Partners IX, LLC | 10% owner | $25M | – | Nov 4, 2026 |
| ARCH Venture Partners IX Overage, L.P. | 10% owner | $12.5M | – | Mar 6, 2026 |
| Lynn Seely | President and CEO, Director | – | $355K | Nov 10, 2026 |
| Veronica Sanchez Bulis | VP, Corporate Controller | – | $99.7K | Nov 10, 2026 |
| Gary K. Lee | Chief Scientific Officer | – | $71.5K | Nov 10, 2026 |
| Stephen J. Hill | Chief Operating Officer | – | $51.2K | Nov 10, 2026 |
| David Shook | Chief Medical Officer | – | $31.3K | Sep 10, 2026 |
| Jarrad Mattieu Aguirre | Chief Medical Officer | – | $3.6K | Oct 12, 2026 |
| Innovative Cellular Therapeutics Holdings Ltd | 10% owner | – | $274 | Jul 17, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
LYEL short interest
Moderate short interest. 5.7% of LYEL shares are sold short: about 1 share in 17. Over the last 12 reports the number of shares short went up 5%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 1.41M LYEL shares were sold short, 5.7% of the shares outstanding, up 0.8% from the report before. At the average daily volume of 135,215 shares, buying them all back would take about 10.4 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 1.41M | 5.73% | +1% | 135,215 | 10.4 |
| Oct 15, 2026 | 1.40M | 5.71% | +11% | 178,106 | 7.8 |
| Sep 30, 2026 | 1.26M | 5.16% | +6% | 170,775 | 7.4 |
| Sep 15, 2026 | 1.19M | 4.85% | +5% | 98,363 | 12.1 |
| Aug 31, 2026 | 1.13M | 4.62% | -2% | 127,223 | 8.9 |
| Aug 14, 2026 | 1.15M | 4.70% | -6% | 183,855 | 6.3 |
| Jul 31, 2026 | 1.23M | 5.28% | +1% | 142,256 | 8.7 |
| Jul 15, 2026 | 1.22M | 5.24% | -0% | 182,227 | 6.7 |
| Jun 30, 2026 | 1.22M | 5.25% | -7% | 355,339 | 3.4 |
| Jun 15, 2026 | 1.32M | 5.65% | -3% | 136,926 | 9.6 |
| May 29, 2026 | 1.35M | 5.81% | +1% | 83,489 | 16.2 |
| May 15, 2026 | 1.34M | 5.75% | -0% | 57,657 | 23.2 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Lyell Immunopharma company events
Lyell Immunopharma filed 10 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 4, 2026.
- Nov 4, 2026ResultsReleased financial results. Filing
- Nov 4, 2026SharesSold new shares outside a public offering. Filing
- Sep 10, 2026AnnouncementLyell Immunopharma, Inc. issued a press release regarding the completion of the technology transfer for LYL273 to the Company’s LyFE Manufacturing Facility ™ in Bothell, Washington and an updated timeline on the Phase 1/2 trial evaluating LYL273 in metastatic colorectal cancer. Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Jun 15, 2026VoteReported shareholder vote results. Filing
- May 6, 2026ResultsReleased financial results. Filing
- Mar 12, 2026ResultsReleased financial results. Filing
- Mar 9, 2026LeadershipThe Board of Directors of Lyell Immunopharma, Inc. approved the appointment of Smital Shah as the Company’s Chief Financial and Business Officer and principal financial officer, effective March 9, 2026. Filing
- Dec 8, 2025AnnouncementLyell Immunopharma, Inc. presented at the 67 th American Society of Hematology (ASH) Annual Meeting and Exposition new clinical and translational data from its ongoing clinical trial of rondecabtagene autoleucel (ronde-cel, also known as LYL314) in patients with large B-cell lymphoma. Filing
- Dec 5, 2025RulesChanged its bylaws or articles. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Lyell Immunopharma financials
Famous investors that hold LYEL
4 of the 50 well-known investors we track reported holding LYEL in their latest 13F filing. The largest position is Jim Simons's, worth $1.9M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 189,122 | $1.9M | 0.0% | +45% |
| Israel Englander · Millennium Management | Q3 2026 | 141,059 | $1.4M | 0.0% | -62% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 106,744 | $1M | 0.0% | +471% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 56,992 | $558K | 0.0% | +119% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named LYEL in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 10, 2026 | ARCH Venture Fund IX, L.P. | 13G/A | 17.4% |
| Nov 10, 2026 | ARCH Venture Fund IX, L.P. | 13G/A | 17.4% |
Questions about Lyell Immunopharma, Inc. (LYEL) stock
Who owns the most LYEL stock?
The largest reported owner of Lyell Immunopharma, Inc. (LYEL) is ARCH Venture Management, LLC, with 13.9% of the company. In total, 87 funds and institutions reported holding LYEL at the end of Q2 2026, together about 52% of the shares. See the largest owners.
Are LYEL insiders buying or selling?
In the last 12 months, LYEL insiders reported 2 open-market purchases worth $37.5M and 29 sales worth $613K. The latest trade was on Nov 10, 2026. See every trade.
What is the short interest in LYEL?
As of Oct 30, 2026, 1.41M LYEL shares were sold short, 5.7% of the shares outstanding, up 0.8% from the report before. At the average daily volume of 135,215 shares, buying them all back would take about 10.4 trading days (days to cover). See the history.
Which famous investors hold LYEL?
4 of the 50 well-known investors we track reported LYEL in their latest 13F filing, including Jim Simons, Israel Englander, Ken Griffin. The largest position is worth $1.9M. See all holders.
Executive pay
Lyell Immunopharma's chief executive was paid a total of $4.2M for the year ended Dec 31, 2025, up 182% from $1.5M the year before. In the last 12 months, Lyell Immunopharma's executives and directors bought no stock on the open market and sold $612K.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.